Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform

Adaptimmune Therapeutics PLC Sponsored ADR +2.01% Pre
Galapagos NV Sponsored ADR -0.42% Pre

Adaptimmune Therapeutics PLC Sponsored ADR

ADAP

1.27

1.27

+2.01%

0.00% Pre

Galapagos NV Sponsored ADR

GLPG

26.37

26.37

-0.42%

0.00% Pre

  • Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer
  • Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform
  • Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development
  • Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales
  • Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via